

10/26/00

JC952 U.S. PTO

FRANK R. AGOVINO
DERICK E. ALLEN
ROBERT M. BAIN
JAMES J. BARTA, JR.
G. HARLEY BLOSSER
JOHN M. BODENHAUSEN
RICHARD L. BRIDGE
JAMES E. BUTLER, PH.D
SARAH J. CHICKOS
J. BENNETT CLARK
JENNIFER E. COOK
DAVID E. CRAWFORD, JR.
MATTHEW L. CUTLER
JAMES E. DAVIS
KATHRYN J. DOTY
ROBERT M. EVANS, JR.
PAUL I.J. FLEISCHUT
MICHAEL E. GODAR
CHRISTOPHER M. GOFF
DAVID W. HARLAN

EDWARD J. HEJLEK
KAREN Y. HUI
KURT F. JAMES
VINCENT M. KEIL
ANTHONY R. KINNEY
BRIAN P. KLEIN
WILLIAM E. LAHEY
PAUL A. MADDOCK
MICHAEL G. MUNSELL
DEBRA D. NYE
KATHLEEN M. PETRILLO
LAURA R. POLCYN
KEITH A. RABENBERG
STEVEN M. RITCHEY
JOHN K. ROEDEL, JR.
JOSEPH A. SCHAPER
RICHARD A. SCHUTH
MEG MARSHALL THOMAS
MICHAEL J. THOMAS
DONALD W. TUEGEL

10-27-00

SENNIGER, POWERS, LEAVITT & ROEDEL
ATTORNEYS AT LAW

ONE METROPOLITAN SQUARE
16TH FLOOR
ST. LOUIS, MISSOURI 63102
314-231-5400

October 26, 2000

FACSIMILE 314-231-4042
http://www.senniger.com

PATENTS, TRADEMARKS, COPYRIGHTS
AND RELATED MATTERS

OF COUNSEL
IRVING POWERS
DONALD G. LEAVITT
RICHARD G. HEYWOOD

STUART N. SENNIGER
(1921-1997)

A
10/26/00
JC952 U.S. PTO
09/697235

UTILITY PATENT APPLICATION TRANSMITTAL
(new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket Number: NVI 5044.1
First Named Inventor: Christopher D. Knight
Express Mail Label Number: EL615276520

TO: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

APPLICATION ELEMENTS

1. ☒ Fee Transmittal Form
(original and duplicate)
2. ☒ Specification [Total Pages 37]
3. ☒ Drawings [Total Sheets 12]
4. Oath or Declaration [Total Pages 8]
 - a. ☐ Newly executed (original or copy)
☐ New (unexecuted)
 - b. ☒ Copy from a prior application
(for continuation/divisional with
Box 17 completed)
 - i. ☐ DELETION OF INVENTOR(s)
Signed statement attached
deleting inventor(s) named
in prior application.
5. ☒ Incorporation By Reference
(useable if Box 4b is marked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 4b, is
considered as being part of the disclosure of the
accompanying application and is hereby incorporated by
reference therein.

09/697235

6. ☐ Microfiche Computer Program (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above
copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ IDS with PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard
14. ☐ Small Entity Statement(s)
☐ Statement filed in prior application; status still
proper and desired
15. ☐ Certified Copy of Priority Document(s) if foreign
priority is claimed
16. ☐ Other: _____

**IF A CONTINUING APPLICATION, CHECK APPROPRIATE
BOXES AND SUPPLY THE REQUISITE INFORMATION**

17. ☒ Continuation ☐ Divisional ☐ Continuation-in-Part
of prior application No.: 09/333,095
- ☐ Complete Application based on provisional Application
No. _____

CORRESPONDENCE ADDRESS

18. Correspondence Address: Customer Number 321
Attention: Anthony R. Kinney

Respectfully submitted,



Anthony R. Kinney, Reg. No. 44,834

ARK/leb

Demographic Data	
Age (years)	Mean = 30.5
Gender	Male = 15, Female = 15
Education	High school = 10, College = 5
Occupation	Student = 10, Worker = 5
Psychological Data	
Stress (scale 1-10)	Mean = 6.5
Depression (scale 1-10)	Mean = 4.5
Anger (scale 1-10)	Mean = 5.5
Loneliness (scale 1-10)	Mean = 6.0
Self-esteem (scale 1-10)	Mean = 7.0
Life satisfaction (scale 1-10)	Mean = 6.5
Resilience (scale 1-10)	Mean = 7.5
Optimism (scale 1-10)	Mean = 7.0
Neuroticism (scale 1-10)	Mean = 5.5
Extraversion (scale 1-10)	Mean = 6.5
Conscientiousness (scale 1-10)	Mean = 7.0
Agreeableness (scale 1-10)	Mean = 7.5
Openness (scale 1-10)	Mean = 7.0
Intelligence (scale 1-10)	Mean = 8.0
Memory (scale 1-10)	Mean = 7.5
Attention (scale 1-10)	Mean = 7.0
Perception (scale 1-10)	Mean = 7.5
Emotion (scale 1-10)	Mean = 7.0
Behavior (scale 1-10)	Mean = 7.5
Thought (scale 1-10)	Mean = 7.0
Feeling (scale 1-10)	Mean = 7.5
Understanding (scale 1-10)	Mean = 7.0
Communication (scale 1-10)	Mean = 7.5
Relationship (scale 1-10)	Mean = 7.0
Health (scale 1-10)	Mean = 7.5
Environment (scale 1-10)	Mean = 7.0
Society (scale 1-10)	Mean = 7.5
Future (scale 1-10)	Mean = 7.0
Past (scale 1-10)	Mean = 7.5
Present (scale 1-10)	Mean = 7.0
Life (scale 1-10)	Mean = 7.5
World (scale 1-10)	Mean = 7.0
Universe (scale 1-10)	Mean = 7.5
Existence (scale 1-10)	Mean = 7.0
Reality (scale 1-10)	Mean = 7.5
Truth (scale 1-10)	Mean = 7.0
Justice (scale 1-10)	Mean = 7.5
Love (scale 1-10)	Mean = 7.0
Peace (scale 1-10)	Mean = 7.5
Harmony (scale 1-10)	Mean = 7.0
Balance (scale 1-10)	Mean = 7.5
Equilibrium (scale 1-10)	Mean = 7.0
Stability (scale 1-10)	Mean = 7.5
Consistency (scale 1-10)	Mean = 7.0
Reliability (scale 1-10)	Mean = 7.5
Trustworthiness (scale 1-10)	Mean = 7.0
Honesty (scale 1-10)	Mean = 7.5
Integrity (scale 1-10)	Mean = 7.0
Character (scale 1-10)	Mean = 7.5
Personality (scale 1-10)	Mean = 7.0
Identity (scale 1-10)	Mean = 7.5
Self (scale 1-10)	Mean = 7.0
Other (scale 1-10)	Mean = 7.5
Us (scale 1-10)	Mean = 7.0
Them (scale 1-10)	Mean = 7.5
It (scale 1-10)	Mean = 7.0
That (scale 1-10)	Mean = 7.5
This (scale 1-10)	Mean = 7.0
These (scale 1-10)	Mean = 7.5
Those (scale 1-10)	Mean = 7.0
Such (scale 1-10)	Mean = 7.5
Like (scale 1-10)	Mean = 7.0
Unlike (scale 1-10)	Mean = 7.5
Similar (scale 1-10)	Mean = 7.0
Different (scale 1-10)	Mean = 7.5
Same (scale 1-10)	Mean = 7.0
Other (scale 1-10)	Mean = 7.5
Various (scale 1-10)	Mean = 7.0
Many (scale 1-10)	Mean = 7.5
Few (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0
Some (scale 1-10)	Mean = 7.5
None (scale 1-10)	Mean = 7.0
All (scale 1-10)	Mean = 7.5
Each (scale 1-10)	Mean = 7.0
Every (scale 1-10)	Mean = 7.5
Any (scale 1-10)	Mean = 7.0

jc813 U.S. PTO
09/697235
10/26/00

1. [] The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345, in the name of Senniger, Powers, Leavitt & Roedel.

 [] The Commissioner is hereby authorized to charge any additional filing and claim fees under 37 CFR 1.16 and application processing fees under 37 CFR 1.17 to Deposit Account No. 19-1345, in the name of Senniger, Powers, Leavitt & Roedel.
2. [X] Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345, in the name of Senniger, Powers, Leavitt & Roedel.

1. [X] BASIC FILING FEE \$690.00 (Type: Continuation)
Entity Status: large

2. [X] CLAIM FEE \$306.00

Total Claims 37
Independent Claims 1
Multiple Dependent Claims --

3. [] ADDITIONAL FEES \$_____

[] Surcharge - late filing fee or oath
[] Surcharge - late provisional filing fee or cover
sheet
[] Extension for reply within _____ month
[] Notice of Appeal
[] Filing a Brief in Support of an appeal
[] Request for Reexamination
[] Petitions to the Commissioner
[] Submission of Information Disclosure Statement
[] Recording each patent assignment per property
[] Other:

Anthony R. Kinney, Reg. No. 44,834 October 26, 2000
Date

ARK/leb

PROCESS FOR OPTIMIZING MILK PRODUCTIONCROSS-REFERENCE TO RELATED APPLICATION

This application is a complete application based on U.S. application Serial No. 09/033,095, filed June 15, 1999, which is a continuation application of U.S. application Serial No. 08/900,414, filed July 25, 1997, the entire disclosure of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

The present invention generally relates to a process for satisfying the nutritional requirements of ruminants for methionine, and more specifically, to a process for meeting those nutritional requirements using the hydroxy analog of methionine (2-hydroxy-4(methylthio)butanoic acid) and its salts, amides and esters.

High producing dairy cows need methionine, lysine and other key essential amino acids to reach their genetic potential for milk production. While amino acids can be added directly to the diets of monogastric animals to overcome nutritional deficiencies, free amino acids are rapidly degraded by rumen bacteria and are of little or no practical benefit in alleviating amino acid deficiencies in ruminants.

Traditionally, undegradable intake protein ("UIP") such as blood meal, fish meal, corn gluten meal and others have been used to provide essential amino acids to

ruminants. It is difficult, however, to accurately deliver needed levels of methionine and other essential amino acids without providing excess levels of other non-essential amino acids and, any excess nitrogen which UIP
5 delivers to the rumen must be degraded and eliminated by the animal. Consequently, formulating feeds which satisfy the methionine requirements using UIP sources is not only expensive, it can also affect cow health and productive status.

10 As an alternative to UIP, attempts have been made to modify or protect methionine in a manner so that it is not susceptible, or at least is less susceptible, to rumen degradation. Various "coatings" for methionine have been proposed which, in theory, enable the rumen
15 protected methionine ("RPM") to clear or "bypass" the rumen without significant destruction by rumen microflora and deliver this key amino acid to the small intestine. Once in the small intestine, the coating dissolves thereby freeing the methionine which is absorbed from the
20 intestine.

The practical application of rumen protected methionine, however, has presented some challenges. For example, some products have limited solubility. For others, pelleting, expander conditioning, mixing, and
25 other normal milling practices fracture the protective coating, making the methionine molecule vulnerable to rumen degradation. Some dairy producers have circumvented this problem by top dressing the rumen

protected methionine on final rations. This labor intensive practice, however, does not allow the ingredient to be uniformly distributed in the diet. As a result, cows within a herd may consume different amounts of methionine.

It has been reported that the milk production of dairy cows can be increased by supplementing the diets of the cows with the hydroxy analog of methionine and its salts and esters. See, e.g., U.S. Patent No. 4,388,327. Previous attempts to implement this technology, however, were met with unpredictable milk production responses.

More recently, the calcium salt and the free acid forms of the hydroxy analog of methionine have been combined with bypass fats in a dry product for use as an ingredient of a ruminant food ration. As understood, the level of inclusion of the bypass fat/hydroxy analog dry product has been determined using a computer model which matches the nutritional requirements of the ruminant with available feed ingredients. This approach, however, suffers from several disadvantages. Because the two ingredients are combined in a predetermined ratio, the product offers less flexibility in formulating a ration which meets a least cost objective and precludes the possibility of formulating a feed ration which includes the hydroxy analog of methionine but not bypass fat. In addition, the dry form of the product is susceptible to the formation of undesirable dust and to non-uniform mixing with other feed ration ingredients.

SUMMARY OF THE INVENTION

Among the objects of the invention, therefore, is the provision of a process for satisfying the nutritional requirements of ruminants for methionine, the provision of such a process in which it is unnecessary to coat or otherwise protect the methionine source from rumen microflora, the provision of such a process in which a predictable milk response is obtained, the provision of such a process which avoids providing excess levels of fats or other non-essential amino acids to the ruminant in order to satisfy the methionine needs, and the provision of such a process in which some of the UIP in a balanced ration may be replaced with a lower cost source of methionine to yield a cost improvement.

Briefly, therefore, the present invention is directed to a process for formulating a ruminant food ration for a ruminant. In this process, the methionine needs of the ruminant are determined. A plurality of natural or synthetic feed ingredients and the nutrient composition of each of said ingredients is identified wherein one of said ingredients is 2-hydroxy-4-(methylthio)butanoic acid or a salt, amide or ester thereof. From the identified feed ingredients, a ration is formulated to meet the determined methionine needs of the ruminant which comprises one or more grains, a hydroxy analog of methionine, and optionally a bypass fat wherein (i) the hydroxy analog of methionine is selected from the group consisting of 2-hydroxy-4-

(methylthio)butanoic acid and the salts, amides and esters thereof, (ii) the hydroxy analog of methionine is added separately from any bypass fat which is included in the ration, and (iii) the ration is formulated on the basis that at least 20% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

Other objects and features of this invention will be in part apparent and in part pointed out hereinafter.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph of HMB (DL, 2-hydroxy-4-[methylthio]butanoic acid) versus time for the study of Example 1.

Fig. 2 is a graph of HMB (DL, 2-hydroxy-4-[methylthio]butanoic acid) concentration in the duodenum versus time for the study of Example 1.

Fig. 3 is a graph of chromium concentration in the rumen versus time for the study of Example 1.

Fig. 4 is a graph of chromium concentration in the duodenum versus time for the study of Example 1.

Fig. 5 is a graph showing rumen and duodenal HMB (DL, 2-hydroxy-4-[methylthio]butanoic acid) and serum methionine response following oral dosing of 90 g HMB in lactating dairy cows for the study of Example 1.

Fig. 6 is a graph showing milk production (kg/d) versus time for the study of Example 2.

Fig. 7 is a graph showing fat percentage in milk versus time for the study of Example 2.

Fig. 8 is a graph showing fat corrected milk yield (kg/d) versus time for the study of Example 2.

5 Fig. 9 is a graph showing protein percentage in milk versus time for the study of Example 2.

Fig. 10 is a graph showing milk production (lb./cow/day) versus time for the study of Example 4.

10 Fig. 11 is a graph showing milk protein (lb./cow/day) versus time for the study of Example 4.

Fig. 12 is a graph showing milk fat (lb./cow/day) versus time for the study of Example 4.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Optimizing milk production in ruminants requires
15 matching the nutritional requirements of the ruminant with least cost sources from available feed ingredients. In recent years, several computer models have been developed for this purpose; these models enable a dairy nutritionist to predict the methionine and other nutrient
20 requirements for high milk producing dairy cows and to formulate a feed ration using least cost sources. Two of the more well known models are the Cornell Net Carbohydrate and Protein System (CNCPS) and the University of Pennsylvania DAIRYLP program. See, Fox,
25 D.G., Using Computer Models in Extension to Develop More Profitable Feeding Systems, Internet Text Address: [HTTP://www.inform.umd.edu](http://www.inform.umd.edu); Galligan, D.T., J.D. Ferguson,

009207 "EE245950

C.F.Ramberg, Jr. and W. Chalupa. 1986. Dairy Ration
Formulation and Evaluation Program for Microcomputers.
J.Dairy Sci. 69:1656; Galligan, D.T., C.F. Ramberg, Jr.,
W. Chalupa and J.D. Ferguson. 1989. J.Dairy Sci. 72:suppl

5 1):445. In general, the computer models use input data
such as animal type, body weight, fat test, milk
production level, environmental conditions, nutrient
composition of available feeds, feed cost, and rumen
bypass rates for degradable protein and amino acid
10 sources. From this information, the models formulate a
least cost feed ration which accurately meets the
ruminant's nutritional requirements to support the
desired level of milk production from available sources
which typically will include corn, soy, alfalfa,
15 vitamins, minerals, molasses, fat sources, amino acid
sources, undegradable intake protein, and a variety of
other feedstuffs.

Depending upon the dose, location of administration
and diet or management factors, experimental evidence to
20 date suggests that the amount of methionine hydroxy
analog which bypasses the rumen and is available for
absorption when the analog is fed to a ruminant in the
absence of a bypass fat is at least about 20% on a
molecular basis. Experimental bypass data and field work
25 with dairy cattle (based upon milk response) further
suggests that the amount which by-passes the rumen is at
least about 40% on a molecular basis. Additional
experimental evidence suggests that about 8.8% of the

009207 5526950

analog is absorbed by the omasum and should be available for use. Still further experimental evidence suggests that a certain percentage of methionine hydroxy analog which doesn't clear the rumen is actually absorbed
5 through the rumen's epithelial lining. Everything considered, therefore, the amount of the hydroxy analog of methionine which bypasses the rumen and is available for absorption is between about 40% and about 55%.

In the process of the present invention, a
10 conventional computer model is used to determine the methionine and other nutritional requirements of the ruminant and a least cost feed ration which will meet these requirements is formulated. Advantageously, the feed ration includes the hydroxy analog of methionine and
15 is formulated on the basis that at least 20% of the hydroxy analog is assumed to be available for absorption by the ruminant. Preferably, the ration is formulated on the basis that at least about 40% of the hydroxy analog is assumed to be available for absorption by the ruminant
20 and more preferably on the basis that between about 40% and about 55% of the hydroxy analog is assumed to be available for absorption by the ruminant.

The hydroxy analog of methionine ("MHA") which may be used in the process of the present invention include
25 2-hydroxy-4(methylthio)butanoic acid, its salts, esters, amides, and oligomers. Representative salts of MHA include the ammonium salt, the stoichiometric and hyperstoichiometric alkaline earth metal salts (e.g.,

5

15

25

individually as an ingredient in the grain concentrate portion of the ration; stated another way, the amount of hydroxy analog added to the grain concentrate portion of the ration is independent of the amount of bypass fat added (if any) to the grain concentrate portion.

Preferably, the hydroxy analog of methionine is the free acid which is a liquid offering several handling and mixing advantages. As a liquid, it is evenly absorbed by the grains and does not settle out of the mixture before consumption by the ruminant. Since its availability to the ruminant is not derived by any protective coating, it can be mixed, augered, exposed to high temperature steam conditioning, extruded, expanded or pelleted with no loss of product activity. In addition, once consumed by the ruminant, the hydroxy analog of methionine is subject to no loss of activity resulting from mastication and cud chewing, as are calcium soaps of fatty acids (common bypass fats), amino acids and other nutrients that derived their activity in the ruminant as a result of a protective coating.

In addition, the hydroxy analog of methionine which is incorporated into the grain concentrate need not be coated with or incorporated into a bypass fat in order to be available to the ruminant. This provides added flexibility to allow the hydroxy analog of methionine to be added at the level required given the ration ingredients and the productivity of the cows receiving the ration.

In general, a bypass fat is a fat which has been chemically or physically altered or synthesized to remain insoluble (or inert) as it passes through the rumen of the cow. Bypass fats typically remain as a solid as they pass through the first parts of a ruminant's digestive tract including the rumen. After passing through the rumen, the fat is solubilized in the initial regions of the small intestine and then becomes available to enzymatic activity through well known mechanisms of fat absorption. Some commercially available bypass fats are described, for example, in U.S. Pat. Nos. 5,182,126; 5,250,307; 5,391,787; 5,425,963; and 5,456,927 which disclose C14 - C22 fatty acids, their glycerides, or their salts including, but not limited to, palmitic, oleic, linoleic, stearic, and lauric compounds. As used herein, however, the term bypass fat does not include fats of natural origin which are normally present in the diet of a cow which include, but are not limited to, animal fats such as poultry fat, animal tallow, animal oil, or vegetable oils such as canola oil, coconut oil, corn oil, cottonseed oil, palm oil, peanut oil, poultry fat, sunflower oil, soybean oil, or safflower oil.

To derive benefit from addition of the hydroxy analog of methionine, one needs only verify that the ration fed at expected levels of consumption, is limiting in its content of available methionine. This is achieved through the use of computer models such as the CNCPS and DAIRYLP in conjunction with the supplementation of the

appropriate level of the hydroxy analog of methionine, based on its availability in the ruminant.

As described in greater detail in the examples presented herein, research has confirmed that the hydroxy analog of methionine is readily available as a methionine source for ruminant animals. This work has confirmed the rumen survivability of the hydroxy analog of methionine and its absorption, conversion, appearance in blood plasma as 1-methionine and utilization for milk or muscle tissue. In particular, field trials have demonstrated that the hydroxy analog of methionine statistically increased milk output versus control groups that were verified to be methionine deficient through the use of computer models. In addition, when compared to other sources of rumen protected methionine, or methionine provided via various sources of undegradable intake protein, the hydroxy analog of methionine can be one of the most economical means to provided needed methionine to the ruminant. Formulating a feed ration with the flexibility of being able to identify the specific methionine needs of high producing cows from the methionine hydroxy analog instead of from UIP thus provides cost, herd health, and production advantages to the dairy farm industry.

The following examples will illustrate the invention.

EXAMPLE 1

Objective:

To determine the rumen bypass and gastrointestinal availability of HMB (DL, 2-hydroxy-4-[methylthio]butanoic acid) and the response of serum methionine to HMB supplementation in lactating dairy cows.

Experimental Procedures

The absorption and metabolism of 2-hydroxy-4-[methylthio]butanoic acid sold by Novus International (St. Louis, MO under the Alimet® was measured in four lactating dairy cows fitted with rumen and duodenal T-type cannulae (10 cm distal to the pylorus). The cows were offered a basal diet of barley-based concentrate (Table I) and alfalfa hay. The concentrate was fed at a level of 1 kg for every 2.5 kg of milk produced (Table I) and access to alfalfa hay was ad libitum. In addition, cows received 30 g HMB mixed with 2 kg ground corn grain per day for six days to allow for adaptation of the rumen microflora. Cows were then fed 90 g HMB mixed with the ground corn and were administered 600 ml chromium-EDTA (3 g Cr) (Binnerts et al., "Soluble chromium indicator measured by atomic absorption in digestion experiments" Vet. Rec. (1968) page 470) into the rumen via the rumen cannula. The HMB meal was offered to the cows for 20 minutes prior to the morning feeding and any of the

remaining meal was placed in the rumen via the rumen cannula.

Blood, rumen and duodenal samples were collected at 0, 1, 3, 6, 9, 12 and 24 hours post-HMB-feeding. Blood
5 was collected by jugular veni-puncture into 2x10 ml sterile tubes (Vacutainer Brand SST tubes for serum separation, Bectin Dickenson, Rutherford, NJ), allowed to stand for 30 minutes in an ice bath and centrifuged at 3000 x g to separate the serum from cells. Serum was
10 divided into two fractions. The first fraction was deproteinized by adding an equal volume of acetonitrile and then centrifuging to obtain the supernatant. The deproteinized serum was then frozen (-70°C) until analysis. A second fraction was not deproteinized but
15 directly frozen (-70°C). Rumen fluid (100 ml) collected from several sites within the rumen was strained through four layers of cheesecloth and subsampled. The subsample (30 ml) was acidified with 6 M HCl (0.5 ml) and frozen (-40°C). Duodenal samples collected (100 ml) were also
20 stored frozen (-40°C). Rumen and duodenal samples were later thawed and centrifuged at 23 000 x g, 4°C, for 20 minutes to obtain the clarified supernatant. The clarified rumen and the duodenal samples were then frozen until analysis. Serum was analyzed for methionine and
25 rumen and duodenal samples for HMB. Chromium was measured by atomic absorption spectrophotometry in rumen and duodenal samples that were diluted with an equal volume of a calcium chloride solution to yield samples

with approximately 400 ppm Ca^{2+} (Williams et al., "The determination of chromic oxide in faeces samples by atomic absorption spectrophotometry" *J. Agric. Sci.*, Vol. 59 (1962) pp. 381-385).

5 Results and Discussion

The cows refused to consume the 90 g HMB meal and, therefore, the meal was placed in the rumen. The concentrations of Cr (liquid marker) and HMB in rumen and duodenal fluid for each of the four cows at various times after intraruminal dosing is presented in **Table II** and **Figs. 1 - 4**. When the data was plotted on a semilogarithmic scale (natural logarithm), it followed a straight line (data not shown). The slope of the line from the semilogarithmic plot is equal to the fractional rate constant (K). The rate constants were calculated by linear regression of the natural logarithm of Cr and HMB concentration verses time (**Table III**). Regression analysis of rumen Cr concentration was performed with data for 1 to 24 hours (excluding data for 0 hour). The rumen concentration of HMB declined to levels below the detection limit of the analytical technique ($< 10 \text{ ug/ml}$) by 24 hours and, therefore, regression analysis was performed with data for 1 to 12 hours (excluding data for 0 and 24 hours).

Regression analysis for duodenal Cr and HMB concentration included the data for 3 to 24 hours and 3

to 12 hours, respectively. Excluding the data for 1 hour simplified the analysis by omitting the delay for the translocation of digesta from the rumen to the duodenum. The mathematical equations describing the decline of Cr and HMB in the rumen (R^2 , 0.9855 and 0.9738, respectively) and duodenum (R^2 , 0.9744 and 0.9674, respectively) were well fitted to the data.

Assuming that the decline in rumen HMB concentration is due to the passage of HMB from the rumen and microbial degradation of HMB within the rumen, then the fractional rate constant for HMB (-.3269; **Table III**) in the rumen will equal the sum of the rate constants for the passage and degradation of HMB.

$$K_{[\text{HMB-rumen}]} = K_{[\text{passage}]} + K_{[\text{degradation}]}$$

The HMB is soluble, and therefore, the rate at which HMB passes from the rumen will be equivalent to the rate of passage for Cr, the liquid marker (-.1307). Thus, the rate constant for microbial degradation within the rumen is -.1962 ($K_{[\text{HMB-rumen}]} - K_{[\text{passage}]} = K_{[\text{degradation}]}$). The rumen degradation of HMB was determined based on the ratio of the rate of degradation of HMB to the total rate of decline of HMB (-.1962/- .3269). Thus, 60% percent of the HMB dose disappeared in the rumen with 40% of the dose bypassing the rumen fermentation.

The fractional rate constant for the decline in HMB concentration at the proximal duodenum (-.3380; **Table**

III) is equal to the sum of the rate constants for passage and disappearance of HMB.

$$K_{\text{[HMB-duodenum]}} = K_{\text{[passage]}} + K_{\text{[disappearance]}}$$

The rate constant for passage of HMB ($K_{\text{[passage]}}$) to the duodenum was determined by calculating the rate constant for the passage of the Cr marker (-.1053; **Table III**). Thus, 31.2% of the HMB fed to the cows passed to the small intestine $(-.1053 / -.3380 \times 100)$ and 68.8% disappeared $[(.3380 - (-.1053)) / -.3380 \times 100]$. The K for disappearance at the duodenum includes the K for degradation in the rumen and the K for absorption postruminally but pre-intestinally (presumably the omasum).

$$K_{\text{[disappearance]}} = K_{\text{[rumen degradation]}} + K_{\text{[omasal absorption]}}$$

It was determined from the rumen decline in HMB, that 60% of the HMB disappeared in the rumen. Therefore, the remaining 8.8% of HMB disappearance was due to omasal absorption. Of the original dose of HMB fed to the dairy cows, 60% was degraded in the rumen, 8.8% was absorbed in the omasum and 31.2% passed to the small intestine for absorption. While we have defined ruminal disappearance as degradation, the substantial quantity of omasal absorption of HMB indicates that it is likely that some fraction of the 60% ruminal disappearance may have occurred via absorption through the rumen wall. As HMB

is absorbed via passive diffusion in other species, it is reasonable to expect this phenomenon to occur in rumen epithelium as well. Therefore, the bioavailability of 40% for HMB, as a methionine source for ruminants, is likely a conservative underestimate.

Peak concentrations for ruminal and duodenal HMB occurred at 1 and 3 hours, respectively. Peak serum methionine concentration occurred at 6 hours. By 12 hours, all values had returned to pre-dose levels (**Fig. 5**). The absorption of HMB from the omasum and small intestine and its subsequent metabolism to methionine produced an increase in serum methionine of 200% above pre-dose levels at the peak concentration.

TABLE I
Composition of Concentrate

Item Ingredient, % (as-fed basis)	
Barley grain (medium roll)	51
Rolled corn	10
Beet pulp	8.5
Blood meal	11.5
Soybean meal	4.2
Canola meal	4
Canola oil	3.5
Liquid molasses	2
Mineral premix ¹	2
Sodium bicarbonate	1.5
Dicalcium phosphate	1
Perma-Pell	0.8
Vitamin ADE ²	0.025
Flavor ³	0.017

¹ Supplies per kg of concentrate: Na, 0.7%; S, 0.2%; K, 0.02%; Mg, 0.01%; Zn, 154 mg/kg; Mn, 147 mg/kg; Cu, 40 mg/kg; I, 2 mg/kg; Se, 0.8 mg/kg; and Co, 0.6 mg/kg.

² Supplies per kg of concentrate: vitamin A, 2500 IU; vitamin D, 250 IU; and vitamin E 2.5 IU.

³ ACS Cattle feeding flavor, Alltech, Inc.

TABLE II

Chromium and HMB Concentration in Rumen and Duodenal Fluid

Time (h)	Chromium Concentration (ug/ml)							
	HMB Concentration (ug/ml)							
	124	131	133	138	124	131	133	138
Rumen								
0	0.04	0.07	0.01	0.02	< 10	< 10	< 10	< 10
1	31.83	36.27	40.44	45.51	538.6	615.1	766.6	875.8
3	23.77	29.11	34.52	37.05	326.7	401.1	539.1	656.3
6	19.29	18.09	16.62	27.94	209.9	170.3	173.4	342.0
9	12.93	8.89	10.79	13.89	78.6	50.8	59.3	94.0
12	9.16	5.04	7.86	8.28	22.1	13.2	22.8	19.7
24	3.62	1.07	2.08	1.97	< 10	< 10	< 10	< 10
Duodenum								
0	1.36	0.05	0.05	0.02	< 10	< 10	< 10	< 10
1	11.69	23.80	12.14	17.98	159.3	370.6	189.2	336.8
3	18.30	24.55	25.41	27.23	245.5	324.5	367.5	477.8
6	11.99	17.86	18.42	23.24	81.7	146.2	169.8	276.3
9	11.00	12.16	16.36	19.26	40.6	47.1	70.3	142.7
12	7.89	6.39	7.89	8.39	11.6	13	15.1	25.4
24	3.88	2.06	2.29	2.85	< 10	< 10	< 10	< 10

009201 55225950

Linear Regression Analysis of the Natural Logarithm of Cr and HMB Concentration in Rumen and Duodenal Fluid Verses Time

Chromium						
HMB						
Cow	Constant	K	R ²	Constant	K	R ²
Rumen						
1 to 24 hours						
1 to 12 hours						
24	3.4702	-.0940	.9883	6.7179	-.2809	.9654
131	2.7330	-.1576	.9878	6.9865	-.3506	.9835
133	3.7310	-.1302	.9781	7.1155	-.3317	.9940
138	3.9905	-.1411	.9877	7.4596	-.3444	.9524
Mean	3.7312	-.1307	.9855	7.0699	-.3269	.9738
SD	0.2124	.0270	.0049	.3081	.0317	.0185
Fitted Equation $Y = 41.7292e^{-.1307t}$ $Y = 1176.0304e^{-.3269t}$						
Duodenum						
3 to 24 hours						
3 to 12 hours						
124	3.0038	-.0705	.9747	6.4793	-.3285	.9895
131	3.5284	-.1201	.9823	6.9923	-.3595	.9895
133	3.6342	-.1173	.9796	7.1167	-.3486	.9713
138	3.7419	-.1135	.9608	7.3626	-.3155	.9194
Mean	3.4771	-.1053	.9744	6.9877	-.3380	.9674
SD	.3273	.0234	.0096	.3722	.0198	.0331

EXAMPLE 2

In a lactation study, the effects of providing Alimet® (2-hydroxy-4-[methylthio]butanoic acid sold by Novus International (St. Louis, MO)) feed supplement in the close-up pre-lactation dry period and in early lactation diets was evaluated. The diets (**Table IV**) were formulated to include Alimet® to meet the methionine requirements as determined using existing computer modeling technology (CNCPS and DAIRYLP). The diets were balanced to meet amino acid requirements and included standard feed ingredients used in dairy rations. In the absence of added Alimet®, the control diet was predicted to be first limiting in methionine. The estimated need for methionine was approximately 9 grams per day. Alimet® was added assuming an availability to the ruminant of 20%.

This study included 10 multiparous and five primiparous cows per treatment, supplemented with Alimet® for two weeks before calving and for 12 weeks of lactation. The Alimet® treatment group produced more milk (33.9 vs 31.3 kg/d; **Fig. 6**) with a higher fat content (4.01% vs 3.71%; **Fig. 7**) than unsupplemented cows. This resulted in more fat-corrected content (FCM) production for the Alimet-fed cows (33.4 vs 29.2 kg/d; **Fig. 8**) but not milk protein content (**Fig. 9**). At peak milk yield, Alimet-fed multiparous cows produced 7.9 kg/d

more FCM than unsupplemented cows (42.0 vs 34.1 kg/d). The benefits of supplying post ruminal amino acid would appear to be greatest during the close-up dry period and early lactation.

TABLE IV

Basal Ration*	
Barley	27%
Cottonseed	11%
Soy bean meal	6.3%
Corn distillers grain	8.0%
Blood meal	2.0%
Megalac (bypass fat)	2.0%
Alfalfa haylage	24%
Alfalfa hay	17%

*Standard basal diet without Alimet®

EXAMPLE 3

In a field trial, Alimet® (2-hydroxy-4-[methylthio]butanoic acid sold by Novus International (St. Louis, MO) at a 40% bypass estimate) was fed to 75 high producing early lactation cows as part of their diet. The Cornell Net Carbohydrate Net Protein Model was used to evaluate the diet (corn grain based diet) being fed to these cattle. The ration being fed was balanced

for 90 pounds of 3.7% butterfat milk per cow per day. In the absence of added Alimet®, the diet was predicted to be first limiting in methionine.

Seventy five multiparous cows were used in each group. The cows were housed in either side of a modern, well ventilated free stall barn. Cattle were allocated to treatment by calving date. As cows calved they were alternately placed in the Alimet® group or a group fed the same commercial TMR without Alimet®. This commercial TMR represents the standard TMR fed in the field at commercial dairies at that time. Milk production of each cow was measured at every milking until 75 cows had been on Alimet® for approximately 90 days and 75 cows had been on the control TMR for about 90 days.

The statistical model used was for a completely randomized design. This design is established by assigning treatments at random to a previously selected set of experimental units. In this case, the treatments were Alimet® or no Alimet®, and the experimental units were cows that were freshening. Assignment to treatment was completely randomized since it was based on calving order. As previously mentioned, cows were placed alternately into the Alimet® group or treatment group as they calved. The data were analyzed with a one way Analysis of Variance procedure, using the F test to determine statistical differences.

The data indicate that the cows receiving Alimet® produced over 5 pounds more milk per cow per day during

the period of the trial. This production response was significant at the $P < 0.04$ level (**Table V**). One cow was excluded from the control group due to extremely low milk production, therefore only 74 cows were used for

5 statistical analysis. The last cow to complete the 90 days of Alimet® feeding was not used in order to balance cow numbers across treatments. This cow averaged 90 pounds of milk per day. There was no significant difference in days in milk of cows in either group when

10 the trial was concluded.

In conclusion, this data set shows that Alimet® provides an acceptable source of bypass methionine in high producing, early lactation cows, when fed from the beginning of lactation onward, to cows consuming a corn

15 silage based diet.

Table V

ANOVA						
Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	935.57628 48	1	935.5763	4.312277	0.039591	3.905939
Within Groups	31675.637 7	146	216.9564			
Total	32611.213 99	147				

Conclusion:

5 Trial compared two groups of early lactation cows. One group was fed Alimet® and the other was not. The diets were isonitrogenous; the Alimet® diet crude protein level was adjusted to account for the nitrogen provided by the treatment. Both diets were fed as Total Mixed Rations on an ad libitum basis.

10 The data indicate that the feeding of Alimet® resulted in an increase of 5.03 pounds of milk per cow per day. This result is statistically significant at the $P = 0.0396$ level.

EXAMPLE 4

15 In a field trial, Alimet® (2-hydroxy-4-[methylthio]butanoic acid sold by Novus International (St. Louis, MO) at a 40% bypass estimate) was fed to 600 cows of a 1900 cow commercial dairy as part of their standard, commercial ration. Computer models were used to determine methionine deficiency and to balance the ration for Alimet® inclusion. The six hundred cows
20 consumed an average of 3.8 grams of Alimet® per head per day over a 102 day feeding period. In the absence of added Alimet®, the control diet was predicted to be first limiting in methionine. The Alimet® supplemented cows produced an average of 2.67 lb. (1.21 kg) more milk per
25 cow daily. Milk protein yield averaged 0.22 lb. (99.8 g) more per cow daily. Milk fat yield averaged 0.26 lb. (118 g) more per cow daily.

In view of the above, it will be seen that the
5 several objects of the invention are achieved.

As various changes could be made in the above compositions and processes without departing from the scope of the invention, it is intended that all matter contained in the above description be interpreted as illustrative and not in a limiting sense.

We claim:

1. A ruminant feed ration for a ruminant, the ration comprising:

a plurality of natural or synthetic feed ingredients which comprises one or more grains;

5 a hydroxy analog of methionine selected from the group consisting of 2-hydroxy-4-(methylthio)butanoic acid, ammonium salts of 2-hydroxy-4-(methylthio)butanoic acid, alkaline earth salts of 2-hydroxy-4-(methylthio)butanoic acid, alkali earth salts of 2-hydroxy-4-(methylthio)butanoic acid, zinc salts of 2-hydroxy-4-(methylthio)butanoic acid, alkane esters of 2-hydroxy-4-(methylthio)butanoic acid, alkane amides of 2-hydroxy-4-(methylthio)butanoic acid, and oligimers of 2-hydroxy-4-(methylthio)butanoic acid, and
10 and, optionally a bypass fat;

15 wherein the amount of hydroxy analog of methionine is included within the ruminant feed ration at a level determined to be necessary to meet the methionine requirements of the ruminant, said methionine requirements being determined from the nutritional
20 content of the ingredients other than the hydroxy analog of methionine and on the basis that at least 20% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

009204-5226960

2. The ruminant feed ration of claim 1 wherein the hydroxy analog of methionine is a salt of 2-hydroxy-4-(methylthio) butanoic acid selected from the group consisting of ammonium, magnesium, calcium, lithium,
5 sodium, potassium, and zinc.

3. The ruminant feed ration of claim 2 wherein at least 40% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

4. The ruminant feed ration of claim 2 wherein about 40% to about 55% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

5. The ruminant feed ration of claim 1 wherein the hydroxy analog of methionine is an ester of 2-hydroxy-4-(methylthio) butanoic acid selected from the group consisting of methyl, ethyl, 2-propyl, butyl, and 3-methylbutyl.
5

6. The ruminant feed ration of claim 5 wherein at least 40% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

7. The ruminant feed ration of claim 5 wherein about 40% to about 55% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

8. The ruminant feed ration of claim 5 wherein the hydroxy analog of methionine is 2-propyl ester of 2-hydroxy-4-(methylthio)butanoic acid.

9. The ruminant feed ration of claim 1 wherein the hydroxy analog of methionine is an amide of 2-hydroxy-4-(methylthio) butanoic acid selected from the group consisting of methylamide, dimethylamide,
5 ethylmethylamide, butylamide, dibutylamide, and butylmethylamide.

10. The ruminant feed ration of claim 9 wherein at least 40% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

11. The ruminant feed ration of claim 9 wherein about 40% to about 55% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

12. The ruminant feed ration of claim 1 wherein the hydroxy analog of methionine is an oligimer of 2-hydroxy-4-(methylthio) butanoic acid selected from the group consisting of dimers, trimers, and tetramers of 2-
5 hydroxy-4-(methylthio) butanoic acid.

13. The ruminant feed ration of claim 12 wherein at least 40% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

14. The ruminant feed ration in any of claim 1 wherein the ruminant feed ration does not comprise a bypass fat.

15. The ruminant feed ration of claim 1 wherein the amount of the hydroxy analog of methionine is determined by a nutritional model wherein the nutritional model is a computer program.

16. A total mixed ration wherein the ruminant feed ration of claim 1 is mixed with forage.

17. The total mixed ration of 16 wherein the forage is a haylage, silage, or mixture thereof.

18. A process for satisfying the nutritional requirements of a ruminant for methionine wherein the ruminant feed ration of claim 1 is provided to the ruminant.

19. The process of claim 18 wherein the ruminant feed ration is provided to a ruminant during the early lactation period or close-up dry period of the ruminant's lactation cycle.

20. The process of claim 18 wherein the hydroxy analog of methionine is a salt of 2-hydroxy-4-(methylthio)butanoic acid selected from the group consisting of ammonium, magnesium, calcium, lithium, sodium, potassium, and zinc.

21. The process of claim 20, wherein at least 40% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

22. The process of claim 20 wherein about 40% to about 55% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

23. The process of claim 18 wherein the wherein the hydroxy analog of methionine is an amide of 2-hydroxy-4-(methylthio) butanoic acid selected from the group consisting of methylamide, dimethylamide,

5 ethylmethanamide, butylamide, dibutylamide, and
butylmethanamide.

24. The process of claim 23, wherein at least 40%
of the hydroxy analog of methionine is assumed to be
available for absorption by the ruminant.

25. The process of claim 23 wherein about 40% to
about 55% of the hydroxy analog of methionine is assumed
to be available for absorption by the ruminant.

26. The process of claim 18 wherein the wherein the
hydroxy analog of methionine is an ester of 2-hydroxy-4-
(methylthio) butanoic acid selected from the group
consisting of methyl, ethyl, 2-propyl, butyl, and 3-
5 methylbutyl.

27. The process of claim 26, wherein at least 40%
of the hydroxy analog of methionine is assumed to be
available for absorption by the ruminant.

28. The process of claim 26 wherein about 40% to
about 55% of the hydroxy analog of methionine is assumed
to be available for absorption by the ruminant.

29. The process of claim 26 wherein the hydroxy
analog of methionine is a 2-propyl ester of 2-hydroxy-4-
(methylthio) butanoic acid.

009207 55245960
0965733 10500

30. The process of claim 18 wherein the wherein the hydroxy analog of methionine is an oligimer of 2-hydroxy-4-(methylthio) butanoic acid selected from the group consisting of dimers, trimers, and tetramers of 2-
5 hydroxy-4-(methylthio) butanoic acid.

31. The process of claim 30, wherein at least 40% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

32. The process of claim 30 wherein about 40% to about 55% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

33. The process of claim 18 wherein the amount of the hydroxy analog of methionine within the feed ration is determined by a nutritional model wherein the nutritional model is a computer program.

34. The process of claim 18 wherein the ruminant is a dairy cow.

35. The process of claim 34 wherein milk produced by the dairy cow contains increased protein content.

36. The process of claim 34 wherein milk produced contains increased fat content.

009201-5226950

37. The process of claim 34 wherein the volume of milk produced is increased.

1. Demographic characteristics	
Age (years)	50.0
Gender	Male 50.0
Marital status	Married 50.0
Education	High school 50.0
Occupation	Professional 50.0
Income	\$50,000 50.0
Health status	Good 50.0
Smoking status	Non-smoker 50.0
Alcohol consumption	None 50.0
Exercise	Regular 50.0
Stress level	Low 50.0
Family size	2-3 children 50.0
Religious affiliation	Christian 50.0
Political affiliation	Democrat 50.0
Travel frequency	Domestic 50.0
Travel destination	Europe 50.0
Travel duration	1-2 weeks 50.0
Travel companions	Family 50.0
Travel expenses	\$1,000 50.0
Travel satisfaction	High 50.0
Travel frequency	Domestic 50.0
Travel destination	Europe 50.0
Travel duration	1-2 weeks 50.0
Travel companions	Family 50.0
Travel expenses	\$1,000 50.0
Travel satisfaction	High 50.0


PROCESS FOR OPTIMIZING MILK PRODUCTIONAbstract for the Disclosure:

5 A process for formulating a ruminant food ration in which the methionine needs of the ruminant are determined, a plurality of natural or synthetic feed ingredients and the nutrient composition of each of said ingredients are identified wherein one of said ingredients is 2-hydroxy-4-(methylthio)butanoic acid or a salt, amide or ester thereof, and a ration is formulated from the identified feed ingredients to meet the determined methionine needs of the ruminant which comprises one or more grains, a hydroxy analog of methionine, and optionally a bypass fat wherein (i) the hydroxy analog of methionine is selected from the group consisting of 2-hydroxy-4-(methylthio)butanoic acid and the salts, amides and esters thereof, (ii) the hydroxy analog of methionine is added separately from any bypass fat which is included in the ration, and (iii) the ration is formulated on the basis that at least 20% of the hydroxy analog of methionine is assumed to be available for absorption by the ruminant.

005207 512/5950

1/12


FIG. 1



2/12

009207 SE226560


FIG. 2



3/12

009201" 5E2/6960


FIG. 3



4/12


009207 5226960

FIG. 4



009207 SE226960

FIG. 5



6/12

009207 522/5950

FIG. 6






FIG. 7



00000T 5826360


FIG. 8



● ALIMET ○ CONTROL


003207 SE 24 950

FIG. 9




009207 SE226960

FIG. 10




00000T 00000000

FIG. 11



009207 SEP 26 1960

FIG. 12



EXPRESS MAIL NO. EL615276520

Attorney's Docket No. NVI 4677

DECLARATION

REGULAR OR DESIGN APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PROCESS FOR OPTIMIZING MILK PRODUCTION

the specification of which:

(check one)

- ☐ is attached hereto
☒ was filed on July 25, 1997 as Application Serial No. 08/900,414, and was amended on _____
☐ was described and claimed in PCT International Application No. _____, filed on _____ and as amended under PCT Article 19 on _____, if any.

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a) - (d) or §365(b) of any foreign application for patent or inventor's certificate, or §365(a) of any PCT application which designates at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)

Priority Not Claimed

ANY FOREIGN APPLICATION(S), ON THE SAME SUBJECT MATTER WHICH HAS A FILING DATE EARLIER THAN THE EARLIEST APPLICATION FROM WHICH PRIORITY IS CLAIMED

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
-------------------	--------------------	---------------------------------

CLAIM FOR BENEFIT OF PROVISIONAL APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

CLAIM FOR BENEFIT OF EARLIER U.S. APPLICATION(S) UNDER 35 U.S.C. 120

(complete this part only if this is a divisional, continuation or CIP application)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____ (Serial No.)	_____ (Filing Date)	_____ (Status: patented, pending, abandoned)
_____ (Serial No.)	_____ (Filing Date)	_____ (Status: patented, pending, abandoned)

Send Correspondence To:

Direct Telephone Calls To:

Customer Number: 000321

Edward J. Hejlek
(314) 231-5400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

- - - - -

Full name of joint inventor Christopher D. Knight
 Residence St. Louis, Missouri Citizenship U.S.A.
 Post Office address 31 Ranch Court
St. Louis, Missouri 63146

Full name of joint inventor Karen M. Koenig

Joint inventor's signature *Karen Koenig* Date 2 June 1998
 Residence Lethbridge, Alberta Citizenship Canada
 Post Office address 1236 5A Avenue South
Lethbridge, Alberta, Canada T1J 0Y2

Full name of joint inventor Lyle M. Rode

Joint inventor's signature *Lyle Rode* Date 2 June 1998
 Residence Lethbridge, Alberta Citizenship Canada
 Post Office address 3302 Beauvais Place South
Lethbridge, Alberta, Canada T1K 3J5

Full name of inventor Michael J. Vandenberg
 Residence St. Louis, Missouri Citizenship U.S.A.
 Post Office address 7901 Teasdale Court
St. Louis, Missouri 63130

Full name of inventor Mercedes Vazquez-Anon
 Residence Chesterfield, Missouri Citizenship U.S.A.
 Post Office address 727 Forest Trace Drive
Chesterfield, Missouri 63017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Christopher D. Knight et al.

Art Unit 1761

Serial No. 08/900,414

Filed July 25, 1997

For PROCESS FOR OPTIMIZING MILK PRODUCTION

Examiner Nina Bhat

POWER OF ATTORNEY

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Irving Powers (15,700), Donald G. Leavitt (17,626), John K. Roedel, Jr. (25,914), Michael E. Godar (28,416), Edward J. Hejlek (31,525), William E. Lahey (26,757), Richard G. Heywood (18,224), Frank R. Agovino (27,416), Kurt F. James (33,716), G. Harley Blosser (33,650), Paul I. J. Fleischut (35,513), Vincent M. Keil (36,838), Robert M. Evans, Jr. (36,794), Robert M. Bain (36,736), Joseph A. Schaper (30,493), Kathleen M. Petrillo (35,076), Rudolph A. Telscher, Jr. (36,032), Paul A. Stone (38,628), David E. Crawford, Jr. (38,118), Paul A. Maddock (37,877), Charles E. Cohen (34,565), Scott A. Williams (39,876), Richard L. Bridge (40,529), David M. Gryte (41,809), and Christopher M. Goff (41,785).

Send Correspondence To:

Direct Telephone Calls To:

Customer Number: 000321

Edward J. Hejlek
(314) 231-5400

Full name of joint inventor Karen M. Koenig

Inventor's signature Karen Koenig Date 12-8-98

Full name of joint inventor Lyle M. Rode

Inventor's signature Lyle Rode Date 12-8-98

Attorney's Docket No. NVI 4677

DECLARATION

REGULAR OR DESIGN APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PROCESS FOR OPTIMIZING MILK PRODUCTION

the specification of which:

(check one)

- ☐ is attached hereto
☒ was filed on July 25, 1997 as Application Serial No. 08/900,414, and was amended on _____
☐ was described and claimed in PCT International Application No. _____, filed on _____ and as amended under PCT Article 19 on _____, if any.

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a) - (d) or §365(b) of any foreign application for patent or inventor's certificate, or §365(a) of any PCT application which designates at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)

Priority Not Claimed

ANY FOREIGN APPLICATION(S), ON THE SAME SUBJECT MATTER WHICH HAS A FILING DATE EARLIER THAN THE EARLIEST APPLICATION FROM WHICH PRIORITY IS CLAIMED

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
-------------------	--------------------	---------------------------------

CLAIM FOR BENEFIT OF PROVISIONAL APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

CLAIM FOR BENEFIT OF EARLIER U.S. APPLICATION(S) UNDER 35 U.S.C. 120

(complete this part only if this is a divisional,
continuation or CIP application)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____ (Serial No.)	_____ (Filing Date)	_____ (Status: patented, pending, abandoned)
_____ (Serial No.)	_____ (Filing Date)	_____ (Status: patented, pending, abandoned)

POWER OF ATTORNEY

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Irving Powers (15,700), Donald G. Leavitt (17,626), John K. Roedel, Jr. (25,914), Michael E. Godar (28,416), Edward J. Hejlek (31,525), William E. Lahey (26,757), Richard G. Heywood (18,224), Frank R. Agovino (27,416), Kurt F. James (33,716), G. Harley Blosser (33,650), Paul I. J. Fleischut (35,513), Vincent M. Keil (36,838), Robert M. Evans, Jr. (36,794), Robert M. Bain (36,736), Joseph A. Schaper (30,493), Kathleen M. Petrillo (35,076), Patrick A. Lujin (35,260), Rudolph A. Telscher, Jr. (36,032), Paul A. Stone (38,628), David E. Crawford, Jr. (38,118), Paul A. Maddock (37,877), Charles E. Cohen (34,565), Scott A. Williams (39,876), Richard L. Bridge (40,529), David M. Gryte (P-41,809), and Christopher M. Goff (P-41,785).

Send Correspondence To:

Direct Telephone Calls To:

Customer Number: 000321

Edward J. Hejlek
(314) 231-5400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of joint inventor Christopher D. Knight

Inventor's signature *Christopher D. Knight* Date 6/2/98
 Residence St. Louis, Missouri Citizenship U.S.A.
 Post Office address 31 Ranch Court
St. Louis, Missouri 63146

Full name of joint inventor Karen M. Koenig
 Residence Lethbridge, Alberta Citizenship Canada
 Post Office address 1236 5A Avenue South
Lethbridge, Alberta, Canada T1J 0Y2

Full name of joint inventor Lyle M. Rode
 Residence Lethbridge, Alberta Citizenship Canada
 Post Office address 3302 Beauvais Place South
Lethbridge, Alberta, Canada T1K 3J5

Full name of inventor Michael J. Vandenberg

Joint inventor's signature *M J Vandenberg* Date 6/3/98
Residence St. Louis, Missouri Citizenship U.S.A.
Post Office address 7901 Teasdale Court
St. Louis, Missouri 63130

Full name of inventor Mercedes Vazquez-Anon

Joint inventor's signature *Mercedes Vazquez-Anon* Date 6/3/98
Residence Chesterfield, Missouri Citizenship U.S.A.
Post Office address 727 Forest Trace Drive
Chesterfield, Missouri 63017

009207 55226960